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ATF = activating transcription factor; β2m = β2-microglobulin; BiP = glucose-regulated protein 78; ER = endoplasmic reticulum; HC = heavy chain;
HLA = human leukocyte antigen; JNK = c-Jun N-terminal kinase; LPS = lipopolysaccharide; MHC = major histocompatibility complex; ReA = reac-
tive arthritis; SpA = spondyloarthropathies; TNF-α = tumour necrosis factor-α; UPR = unfolded protein response.
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Abstract
Spondyloarthropathies are inflammatory diseases closely
associated with human leukocyte antigen (HLA)-B27 by unknown
mechanisms. One of these diseases is reactive arthritis (ReA),
which is typically triggered by Gram-negative bacteria, which have
lipopolysaccharide as an integral component of their outer
membrane. Several findings in vivo and  in vitro obtained from
patients with ReA and from different model systems suggest that
HLA-B27 modulates the interaction between ReA-triggering
bacteria and immune cells by a mechanism unrelated to the
antigen presentation function of HLA-B27. In this review we piece
together a jigsaw puzzle from the new information obtained from
the non-antigen-presenting effects of HLA-B27.
Introduction
The association between a group of rheumatic diseases called
spondyloarthropathies (SpA) and human leukocyte antigen
(HLA)-B27 has been known for several decades [1,2]. Several
theories have been proposed to clarify the pathogenic role of
HLA-B27 [3-7], many of them based on the idea that classical
function of HLA-B27, antigen presentation to T cells, is
somehow abnormal and leads to the development of
inflammatory diseases. However, the proposed theories about
altered antigen presenting effects of HLA-B27 have not
yielded a widely accepted and comprehensive explanation of
the association of HLA-B27 and SpA.
Reactive arthritis (ReA) is an acute inflammatory joint disease
belonging to the group of SpA. The term ReA was originally
introduced to define a sterile joint inflammation during or after
infection elsewhere in the body [8]. The definition was later
changed because bacterial antigens and nucleic acids from
the causative bacteria were found in the inflamed joints [9-
11]. Today ReA is defined as an asymmetrical inflammatory
oligoarthritis or monoarthritis predominantly affecting the
lower limbs [12], but no established criteria for the diagnosis
of ReA are available [13,14]. It is triggered by infection, most
often in the gut or in the urogenital tract by various facultative
or obligate intracellular Gram-negative bacteria such as
Salmonella (different serotypes), Yersinia enterocolitica,
Yersinia pseudotuberculosis,  Shigella flexneri,  Shigella
sonnei,  Campylobacter jejuni,  Chlamydia trachomatis or
Chlamydia pneumoniae [9,15,16].
Recent studies suggest that in addition to its function as an
antigen-presenting molecule, HLA-B27 might also have other
functions that could modulate the inflammatory response and
thus might cause susceptibility to SpA. Results from these
experiments have offered new information about the abnormal
host–microbe interaction between ReA-triggering bacteria
and an HLA-B27-positive host [17-19]. In this review we
summarize the data obtained from these non-antigen-
presenting effects of HLA-B27 and their association with
ReA.
Molecular characteristics of HLA-B27
HLA-B27 belongs to the major histocompatibility complex
(MHC) class I molecules, which are multisubunit glyco-
proteins constructed in the endoplasmic reticulum (ER).
MHC I complexes contain polymorphic MHC I-encoded
heavy chain (HC), β2-microglobulin (β2m), and a small (usually
8 to 10 amino acid residues long) peptide [17]. Once newly
synthesized HC is glycosylated and sufficient tertiary
structure of the molecule has been achieved, it binds to β2m
with the aid of chaperone molecules and forms a hetero-
dimer, HC–β2m. When the heterodimer is formed, chaperone
molecule calnexin is released; however, the HC–β2m complex
still interacts with the peptide loading complex, which
contains the transporter-associated antigen processing
molecules tapasin, calreticulin and Erp57 (oxidoreductase)
(Fig. 1). The complexes formed are exported to the cell
Review
Aetiology and pathogenesis of reactive arthritis: 
role of non-antigen-presenting effects of HLA-B27
Sanna Vähämiko, Markus A Penttinen and Kaisa Granfors
Department of Bacterial and Inflammatory Diseases, National Public Health Institute, Turku, Finland
Corresponding author: Kaisa Granfors, kaisa.granfors@ktl.fi
Published: 26 May 2005 Arthritis Research & Therapy 2005, 7:136-141 (DOI 10.1186/ar1762)
This article is online at http://arthritis-research.com/content/7/4/136
© 2005 BioMed Central Ltd137
Available online http://arthritis-research.com/contents/7/4/136
surface by means of the Golgi machinery, where the
carbohydrate residues of HCs are modified [17,20,21].
The formation of a stable HC–β2m–peptide complex and the
proper three-dimensional structure of the molecule in the ER
are prerequisites for trafficking to the cell surface. Normally,
sufficient tertiary structure of MHC class I molecules is
relatively easily achieved with the aid of chaperones. However,
HLA-B27 HC has two unusual features. First, the folding rate
of HLA-B27 HC is unusually slow, which leads easily to the
generation of misfolded HLA-B27 HCs in the ER even in the
normal presence of chaperones, β2m and peptide [17].
Second, it is capable of forming aberrant disulphide-linked
dimers [22]. The B pocket is a region of the peptide-binding
groove in MHC class I molecules that has an essential role in
peptide selection [17]. The composition of the B pocket of the
HLA-B27 HC has been shown to determine the folding
efficiency and misfolding phenotype of the HLA-B27 HC,
because the mutation of certain amino acid residues in the B
pocket enhances the folding kinetics of the HLA-B27 HC and
prevents the misfolding of the molecule [17,23].
Furthermore, the dimerization of HLA-B27 HC seems to be
dependent on the composition of the B pocket, because an
unpaired and reactive Cys residue (Cys 67) in the B pocket
seems to form a disulphide link between two HLA-B27 HCs,
allowing dimerization [22,24]. Class I HC dimerization is not a
general phenomenon, but it is not unique either. It has been
shown that HLA-B7 and some mouse HLA class I molecules
can form aberrant dimers [22]. As well as mutating Cys 67,
intermolecular disulphide bond formation can be prevented
by the single substitution of methionine for glutamic acid at
position 45 in the B pocket, even in the presence of Cys 67.
This finding suggested that the proper folding rate of HLA-
B27 HCs can prevent dimerization of the HLA-B27 molecule
[17,18]. Interestingly, the amino acids in the B pocket, which
markedly influence the folding rate and the dimer-forming
capacity of the HLA-B27 HCs, are highly conserved in
disease-associated subtypes of HLA-B27, suggesting that
these non-antigen-presenting functions of HLA-B27 might
have a role in the pathogenesis of SpA [18].
Translocation of protein from the ER to the cell surface
requires proper folding to have occurred; unfolded and mis-
folded proteins accumulate in the ER, which leads to distur-
bances in ER function [17]. To cope with these situations,
cells have evolved an ER stress-induced intracellular signal
transduction pathway, the unfolded protein response (UPR).
In eukaryotic cells, the UPR results in the transcriptional
upregulation of several molecular chaperones and folding
enzymes, which are mainly needed to improve the folding
capacity of the ER [25]. Kinase IRE1, PERK kinase and the
basic leucine-zipper transcription factor activating trans-
cription factor 6 (ATF6) have been identified as proximal
sensors of ER stress. The activation of these molecules
depends on their dissociation from the luminal chaperone
glucose-regulated protein 78 (BiP) [26]. Importantly, ER-
stress induced pathways have been reported to activate
nuclear factor κB (NF-κB) and c-Jun N-terminal kinases
(JNKs), [17] which are critical pathways controlling inflam-
matory response. On the basis of those findings it has been
suggested that the misfolding of HLA-B27 HCs might induce
the UPR, which in turn would modulate an inflammatory
response [17].
Non-antigen-presenting effects of HLA-B27
and ReA
The mechanisms by which HLA-B27 confers disease
susceptibility to SpA have remained elusive despite extensive
studies over the course of 30 years. However, findings
obtained from ReA patients suggest that HLA-B27 modulates
the interplay between ReA-triggering bacteria and immune
cells, leading to abnormal host–microbe interaction. These
findings in vivo have encouraged several scientific groups to
generate model systems in vitro to clarify further whether HLA-
B27 modulates a specific stage of host–microbe interaction
such as invasion, intracellular survival or elimination of the
bacteria. The significant finding obtained from patients
suffering from ReA was also that bacterial antigens derived
from ReA-triggering bacteria (for example lipopolysaccharide
(LPS) and heat shock protein 60 (Hsp60)) were discovered
from the inflamed joints. Because most of the patients
suffering from chronic ReA are HLA-B27 positive, it has been
proposed that inflammatory responses triggered by bacterial
antigens might be altered in HLA-B27-positive patients.
Interaction between HLA-B27-expressing
cells and ReA-triggering bacteria
Indirect evidence suggests that the elimination of ReA-
triggering bacteria might be impaired in patients suffering
Figure 1
Several endoplasmic reticulum (ER)-resident chaperone molecules
(tapasin, transporter-associated antigen processing (TAP), calreticulin
and oxidoreductase ERp57) participate in the assembly of the mature
major histocompatibility complex class I heavy chain (HC)/β2-
microglobulin (β2m)/peptide complex in the ER.138
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from ReA. In Salmonella-triggered ReA, immunoglobulin M
(IgM), immunoglobulin A (IgA) and immunoglobulin G (IgG)
antibody concentrations – and in Yersinia-triggered ReA, IgA
antibody concentrations – are higher and persist longer in the
sera of ReA patients than in patients with the same infection
but without joint complications. Prolonged persistence of IgA
antibodies in the sera suggests that continuous antigenic
stimulation might occur in the intestinal mucosa of ReA
patients [27,28]. In addition, bacterial antigens derived from
the triggering bacteria have been found in the white blood
cells of patients suffering from a chronic form of ReA (most of
the patients are HLA-B27 positive), even years after the onset
of infection [29]. Indirect evidence therefore indicates that
ReA-triggering bacteria might cause chronic infection in
HLA-B27-positive patients and that the bacteria might persist
at the mucosal area.
On the basis of the assumption that the interaction between
ReA-triggering bacteria and HLA-B27-positive host cells is
abnormal, several models have been constructed in vitro. The
possible role of HLA-B27 in the invasion, intracellular survival
or elimination of bacteria has been studied by investigators
from different laboratories with different experimental settings
with the use of diverse host cells and various triggering
stimuli [30]. Results with Salmonella typhimurium, Shigella
flexneri, Escherichia coli or  Yersinia enterocolitica [31,32]
suggested that invasion by these bacteria is decreased in
mouse fibroblasts (L cells) by HLA-B27, but an enhanced
invasion of Salmonella enteritidis and  S. typhimurium was
noticed in an HLA-B27-transfected epithelial cell line [33]. In
contrast, several other studies indicate that HLA-B27 does
not influence the invasion of ReA-triggering bacteria by
various cell types [34,35]. Taken together, these studies
indicate that the uptake of ReA-triggering bacteria might be
modulated by HLA-B27 in some cell types with certain
experimental systems. However, the evidence does not
permit the conclusion that HLA-B27 would modulate the
invasion of ReA-triggering bacteria, leading to the generation
of chronic infection.
All ReA-triggering bacteria are able to survive intracellularly
[30]. Studies have therefore been made to establish whether
HLA-B27 can modulate the intracellular survival of these
bacteria. Monocytes/macrophages are mobile long-lived cells
that are important in limiting infection and restricting the
development of systemic disease in vivo. For example,
survival inside macrophages is essential for Salmonella to
cause an infection [36]. For that reason the interaction
between this ‘first line of defence’ and Salmonella is
especially interesting. One of the major aims of our group has
been to study whether HLA-B27 can modulate the interaction
between monocytes/macrophages and Salmonella. We
observed that the elimination of S. enteritidis is impaired in
HLA-B27-transfected human monocytic cells in comparison
with their HLA-A2-transfected counterparts [37]. Impaired
elimination was also seen in an HLA-B27-positive fibroblast
cell line [38,39], but no modulation by HLA-B27 of the
survival of Salmonella in intestinal epithelial cells was
observed [33]. In addition, the survival of Chlamydia
trachomatis was not reported to be affected by HLA-B27 in a
B cell line [40]. On the basis of the results in vitro from the
studies about the survival of ReA-triggering bacteria inside
the cells, it seems that HLA-B27 modulates the behaviour of
certain host cells in response to ReA-triggering bacteria.
However, several factors may contribute to contradictory or
equivocal results obtained in different laboratories. These
include the cell type used, the growth cycle stage of the host
cells, the bacterial strain used, the growth condition of the
bacteria, the growth stage of the bacteria (exponential versus
stationary) and the multiplicity of infection [41].
Recently, we wished to reveal the cause of the impaired
elimination of S. enteritidis in HLA-B27-transfected human
monocytic cells and to study whether the B pocket of
HLA-B27 HC contributes to these modulatory effects.
Further studies revealed that the cells expressing wild-type
HLA-B27 were more permissive for the intracellular
replication of S. enteritidis than mock-transfected or HLA-A2-
transfected controls. Studies with green fluorescent protein
(GFP)-transformed S. enteritidis confirmed that the increase
in the amount of intracellular bacteria was due to replication
(Fig. 2) [18]. Experiments with different forms of HLA-B27
with amino acid substitutions in the B pocket suggested that
the replication is dependent on glutamic acid at position 45 in
the B pocket of HLA-B27. To investigate whether misfolding
of HLA-B27 would induce a UPR, which in turn would
modulate the regulation of genes important in the control of
intracellular replication of Salmonella in monocytic cells, we
studied whether UPR-induced genes Bip and C/EBP
homologous protein-10 (CHOP) were upregulated. However,
we found no induction of these genes in HLA-B27-
expressing cells, suggesting that HLA-B27 HC misfolding
does not induce UPR in these cells and is therefore not
responsible for the permissive phenotype for the intracellular
Figure 2
Confocal microscopy image of green fluorescent protein-transformed
intracellular Salmonella enteritidis 20 hours after infection of U937
cells transfected with human leukocyte antigen-B27. The black arrow
indicates intracellular Salmonella.139
replication of Salmonella in monocytic cells. Studies are now
in progress to elucidate whether the dimerization of HLA-B27
HC is involved in the development of the permissive
phenotype. If a similar effect also occurs in
monocytes/macrophages of HLA-B27-positive individuals,
this permissive phenotype might confer susceptibility to
Salmonella infections and Salmonella-triggered ReA,
because the ability to survive and proliferate inside
macrophages is known to be crucial for the establishment of
systemic disease by Salmonella [36].
LPS-induced tumour necrosis factor-α α
production and HLA-B27
Culturable bacteria are not present, and nucleic acids from
triggering bacteria have been detected only occasionally, in
synovial samples from patients with enterobacteria-triggered
ReA [37,42]. However, bacterial antigens such as degraded
LPS derived from the causative bacteria have been found in
the affected joints [9,10,29]. Such processed LPS is known
to be a strong antigen and capable of activating inflammatory
reactions, possibly leading to the generation of arthritic
symptoms [43]. It is therefore possible that LPS derived from
ReA-triggering bacteria might induce ReA [30]. The main
LPS-responsive cell population in the joints is monocytes/
macrophages, in which LPS can trigger intracellular signalling
pathways leading to the activation of several cytokines such
as tumour necrosis factor-α (TNF-α) [44]. TNF-α is
considered a central cytokine in the development of arthritis
[45]. Furthermore, trials with anti-TNF-α therapy have proved
efficient in the treatment of SpA, suggesting that TNF-α has a
major role in the pathogenesis of SpA [46,47]. The central
role of TNF-α is further supported by genetic studies on
TNF-α polymorphism, which is associated with the
development of SpA in some populations [48,49].
Because we knew that LPS is found in the inflamed joints of
patients with ReA, that most of the patients with chronic ReA
are HLA-B27 positive and that TNF-α is a central cytokine in
the development of SpA, we sought to study whether HLA-
B27 would modulate LPS-induced TNF-α production.
Monocytes/macrophages are the main LPS-responding cell
population in the joints; we therefore decided to discover
whether HLA-B27 would influence LPS-induced TNF-α
production in these cells. LPS-induced TNF-α production is
controlled by the transcription factor nuclear factor κB (NF-
κB) and mitogen-activated protein kinases (MAPKs; p38, JNK
and extracellular regulating kinases (ERKs)) in monocytes/
macrophages. For that reason we have been studying
whether HLA-B27 would modulate the regulation or
activation of these signalling molecules after stimulation with
LPS. We found that such stimulation led to a faster
degradation of the inhibitory molecule (IκB) bound to NF-κB
and thus allowed faster and prolonged activation of NF-κB in
HLA-B27-expressing cells than HLA-A2 and mock
transfectants. The secretion of TNF-α was also found to be
accelerated in HLA-B27-expressing cells after stimulation
with LPS [19]. In future, our aim is to reveal whether non-
antigen-presenting effects of HLA-B27 contribute to these
modulatory effects, and to study whether other intracellular
signalling pathways important in the control of LPS-induced
TNF-α production occur in HLA-B27-expressing monocytic
cells.
Our results from studies in vitro with cell lines do not
necessarily reflect the situation in the cells of HLA-B27-
positive patients in vivo. However, there is evidence that HLA-
B27 might also modulate LPS-induced TNF-α production in
monocytes/macrophages of HLA-B27-positive patients. It has
been reported that monocytes/macrophages obtained from
HLA-B27-positive patients produce enhanced levels of TNF-α
after challenge with LPS [50]. In addition, when whole blood
cultures were prepared from patients suffering from chronic
iritis (most of the patients were HLA-B27 positive), it was
noticed that these cells produced more TNF-α than the
healthy controls after stimulation with LPS [51]. Other studies
indicate that HLA-B27 does not modulate TNF-α production
in various cell types [52]. However, in those studies the
stimulus used was not LPS. It is therefore possible that HLA-
B27 might specifically modulate LPS-induced TNF-α
production in monocytes/macrophages, but more extensive
studies with patient samples are required to make a definite
conclusion whether HLA-B27 could interfere with LPS-
induced TNF-α production in vivo.
Non-antigen-presenting effects of HLA-B27
and animal models
HLA-B27 transgenic rat and mice models have been
generated to study the role of HLA-B27 in the pathogenesis
of SpA in detail. In the rat model, which has been studied
relatively extensively, a high copy number and overexpression
of HLA-B27 are required for the development of an
inflammatory disease closely resembling SpA [53]. Besides
implicating the direct role of HLA-B27 in the pathogenesis of
SpA, the rat model also provides direct evidence that
commensal enteric bacteria have a crucial role in the
pathogenesis of B27-associated rheumatic disease [54].
Recent studies suggest that non-antigen-presenting effects
of HLA-B27 might have a role in this pathogenesis, because
results indicate that disulphide-linked HC dimers are more
prone to form and bind to the ER chaperone BiP in disease-
susceptible HLA-B27 rats than in disease-resistant HLA-B7
rats [55]. Transgenic mice expressing HLA-B27*05 but not
β2m were reported to develop inflammatory arthritis [56].
Interestingly, HLA-B27 HC dimers have been implicated in
this pathogenesis, because treatment with a specific antibody
for MHC class I HC (HC10) amelioriates arthritic symptoms
in these mice [57]. However, these results have been
questioned by others, because β2m-deficient mice develop
spontaneous arthritis even without the expression of
HLA-B27 [58]. It is therefore possible that β2m deficiency
rather than HLA-B27 expression could cause the arthritic
symptoms seen in these mice.
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Clinical data together with the results obtained from cell line
studies support the direct role of TNF-α in the pathogenesis
of HLA-B27-associated disease. However, there is no direct
evidence indicating that TNF-α would have a central role in
the pathogenesis of the disease in HLA-B27-transgenic
rodents, although recent data show that HLA-B27 tetramers
can induce TNF-α production by binding to paired Ig-like
receptors [59]. The differences between animal models and
differential experimental set-ups have complicated the
interpretation of the results from animal studies, and no
simple explanation for the association of HLA-B27 with
inflammatory diseases has been suggested.
Conclusion
ReA is an acute HLA-B27-associated inflammatory joint
disease triggered by certain bacteria. LPS and nucleic acids
from the bacteria have been isolated from affected joints,
suggesting that bacterial antigens might have a direct role in
the pathogenesis of ReA. However, the exact mechanisms by
which HLA-B27 causes disease susceptibility and ReA
develops are still unclear. Findings in vivo from patients with
ReA, results in vitro and results from animal model systems
suggest that HLA-B27 expression can modulate the
host–microbe interaction. Our studies with cell lines indicate
that HLA-B27-expressing monocytes have a impaired
capacity to resist the intracellular replication of Salmonella.
The permissive phenotype seems to be dependent on one
particular amino acid in the B pocket of HLA-B27 HC.
Interestingly, the folding capacity and dimer formation of
HLA-B27 HC are strictly dependent on this same amino acid,
suggesting that non-antigen-presenting effects of HLA-B27
might influence the capacity of monocytes/macrophages to
control the intracellular replication of Salmonella. In addition,
results obtained by us and others suggest that HLA-B27
might enhance LPS-induced TNF-α production in
monocytes/macrophages. However, the modulatory effects
caused by HLA-B27 are likely to be highly dependent on the
cell type studied and triggering stimulus used. Further studies
are needed with patient samples and cells obtained from
HLA-B27 transgenic animals to elucidate whether these
modulatory effects also occur in vivo. It remains to be seen
whether the susceptibility to SpA and ReA arises from a non-
antigen-presenting effect of HLA-B27 or its altered antigen-
presenting effects, or by combination of these.
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